Genomma Lab Internacional SAB de CV Announces Audited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016
February 26, 2017
Share
Genomma Lab Internacional SAB de CV announced audited consolidated earnings results for the fourth quarter and full year ended December 31, 2016. For the quarter, the company reported net sales of MXN 3,014,878 against MXN 2,674,988 a year ago. EBITDA was MXN 467,240 against LBITDA of MXN 2,280,849 a year ago. Operating income was MXN 451,334 against loss of MXN 2,313,964 a year ago. Net income of majority shareholders was MXN 214,782 against loss of MXN 1,747,811 a year ago. Income before income taxes was MXN 345,862 against loss of MXN 2,472,668 a year ago. Net income was MXN 234,305 against loss of MXN 1,735,445 a year ago. Net cash generated operating activities was MXN 531,050. Investment in fixed assets was MXN 60,351 million. Adjusted EBITDA was MXN 498.1 million against MXN 279.3 million a year ago. The company achieved MXN 632.6 million in free cash flow generation.
For the year, the company reported net sales of MXN 11,626,396 against MXN 11,042,451 a year ago. EBITDA was MXN 2,090,387 against LBITDA of MXN 856,989 a year ago. Operating income was MXN 2,008,042 against loss of MXN 975,221 a year ago. Net income of majority shareholders was MXN 1,412,602 against loss of MXN 1,068,518 a year ago. Income before income taxes was MXN 2,158,693 against loss of MXN 1,454,685 a year ago. Net income was MXN 1,542,198 against loss of MXN 1,012,636 a year ago. Net cash generated operating activities was MXN 1,919,457. Investment in fixed assets was MXN 111,429 million. Net debt amounted to MXN 3.98 billion; a MXN 473.9 million reduction compared to December 2015. This decrease in net debt was primarily due to cash generated from its operations. Adjusted EBITDA for the full year reached MXN 2.21 billion, representing a margin of 19.0%, compared to MXN 1.80 billion in 2015, which represented a margin of 16.3%. The company achieved MXN 1.93 billion in free cash flow generation.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company's product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.